Human placental cell line Jeg-3 can be readily infected by a circulating strain of Zika virus (left panel) and completely protected by treatment with nanchangmycin (right panel). All cells are shown in blue while virally infected cells are stained in green.
Credit: The laboratory of Sara Cherry, Perelman School of Medicine, University of Pennsylvania
PHILADELPHIA – A panel of small molecules that inhibit Zika virus infection, including one that stands out as a potent inhibitor of Zika viral entry into relevant human cell types, was discovered by researchers from the Perelman School of Medicine at the University of Pennsylvania. Publishing in Cell Reports this week, a team led by Sara Cherry, PhD, an associate professor of Microbiology, screened a library of 2,000 bioactive compounds for their ability to block Zika virus infection in three distinct cell types using two strains of the virus.
Zika is an emerging mosquito-borne virus for which there are no vaccines or specific therapeutics. The team used cells lining brain capillaries called endothelium, and cells from placenta, which represent Zika’s route across the blood-brain barrier and the transmission path from mother to child, respectively. The third type – a human osteosarcoma cell line – is a generic model cell. They tested a strain of Zika virus currently circulating in human populations in the Americas and another from Africa, which is the original strain identified in 1947.
Using a microscopy-based assay, they identified 38 molecules from the High-throughput Screening Core at Penn, which Cherry directs, that inhibited Zika virus infection in at least one cell type. Roughly half of the 2,000 molecules tested include FDA-approved molecules used to prevent viral replication in infected cells. Co-author David Schultz, PhD, the Core’s technical director, was instrumental in providing the infrastructure and expertise for this multi-level screen.
“Overall, the most important finding is that we identified nanchangmycin as a potent inhibitor of Zika virus entry across all cell types tested, including endothelial and placental cells, which are relevant to how Zika may enter the fetus,” Cherry said. Nanchangmycin – an antimicrobial indentified in China as part of a natural medicinal products survey -- was also active against other medically relevant viruses, including West Nile, dengue, and chikungunya that use a similar route of entry as Zika.
These viruses enter cells using “clatherin endocytosis.” The virus binds with the host cell’s outer membrane via a pocket lined with a protein called clatherin. This protein-lined sac containing the sequestered virus pinches off to move deeper into the cytoplasm of the cell where the virus enters to replicate.
Nanchangmycin is a “stepping stone to a new class of anti-virals,” Cherry said, because it thwarts this essential mode of entry by viruses like Zika. Future studies will identify the target of this drug and current studies are testing the efficacy of nanchangmycin in animal models of Zika virus infection
Coauthors are Keiko Rausch, Brent Hackett, Nathan Weinbren, Sophia Reeder, Yoel Sadovsky, Christopher Hunter, and Carolyn Coyne.
This study was supported by the National Institutes of Health NIH (R01AI074951, RO1AI122749, R01AI095500), the Linda Montague Investigator, Award, and the Burroughs Wellcome Investigators in the Pathogenesis of Infectious Disease Award.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.